March 9, 2023 07:24 AM ESTUpdated 10:53 AM
R&D

Tagris­so reach­es OS end­point in PhI­II EGFR-mu­tat­ed lung can­cer tri­al

Paul Schloesser

Associate Editor

As­traZeneca put out word Thurs­day morn­ing that its lung can­cer ther­a­py and EGFR in­hibitor Tagris­so met a sec­ondary end­point of over­all …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times